Latest news

Debiopharm further explores the potential of its potent, highly selective WEE1 inhibitor Debio 0123 in phase 1 cancer study

CARB-X Funds The 3rd Round of Debiopharm’s Targeted Antibiotic Program To Combat Resistant N. Gonorrhoeae Infections

Debiopharm to Present Late Breaking Head & Neck Cancer Abstract at the 2020 European Society Of Medical Oncology Congress

Debiopharm Advances into the Highly Anticipated Clinical Phase for their Potent WEE1 Inhibitor

Debiopharm progresses in their stand against drug-resistant N. gonorrhoeae with extended CARB-X funding of their Debio 1453 antibiotic program

Debiopharm releases results of 3 key oncology compound programs at the 2019 American Association for Cancer Research (AACR) Conference in…

Debiopharm International SA Awarded $2.6 Million Grant from CARB-X to Support Development of Debio 1453 to fight drug resistant gonorrhea

Almac Discovery and Debiopharm International SA Announce a Licensing Agreement for the Development of a Novel Wee-1 Inhibitor